Robert Janknegt1*, Roel Van Kampen2,Niels Boone3 and Renée Vossen4
1PhD, Hospital Pharmacist, Clinical Pharmacologist, Zuyderland Medical Centre, The Netherlands
2MD, PhD, Haematologist, Oncologist, Zuyderland Medical Centre, The Netherlands
3Hospital Pharmacist, Clinical Pharmacologist, Zuyderland Medical Centre, The Netherlands
4Clinical Chemistry Specialist, Zuyderland Medical Centre, The Netherlands
*Corresponding Author: Robert Janknegt, PhD, Hospital Pharmacist, Clinical Pharmacologist Sittard, The Netherlands.
Received: October 30, 2020; Published: November 30, 2020
Direct acting anticoagulant drugs [DOACs], consisting of apixaban, dabigatran, edoxaban and rivaroxaban have been available for various indications for 3year [edoxaban] up to over a decade [dabigatran and rivaroxaban]. These medicines have shown good clinical efficacy and are usually well tolerated compared to vitamin K antagonists or low molecular weight heparins. Because none of the DOACs is available as a generic formulation, their relatively high price is a disadvantage compared to vitamin K antagonists.
Citation: Robert Janknegt., et al. “Direct Oral Anticoagulants: Drug Selection by Means of the SOJA Method". Acta Scientific Pharmaceutical Sciences 4.12 (2020): 120-144.
Copyright: © 2020 Robert Janknegt., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Open Access by
Acta Scientific is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at https://actascientific.com
ff
